Pramod Srivastava and Lloyd J. Old identify the human homologue of
the mouse tumor rejection antigen gp96.
Not exact matches
Key studies in
mice showed that NF - κB can mediate immune
rejection of
tumors.
«Although both anti-CTLA-4 and anti-PD-1 improved
tumor rejection,
mice treated with anti-CTLA-4 exhibited superior
tumor control, suggesting the memory T - cell response by this agent is more durable,» said Allison.
The decreased
tumor size and enhanced
tumor rejection in DGKζ - deficient
mice indirectly suggests that enhanced Erk signaling may be superior to enhanced NF - κΒ activation in facilitating T cell activity against
tumor, especially because DKO
mice did not exhibit improved
tumor control relative to DGKζ − / −
mice.
James P. Allison and Matthew Krummel demonstrate that a monoclonal antibody directed against the CTLA - 4 molecule in a
mouse model of melanoma could result in the
rejection of
tumors and that this
rejection also resulted in immunity to a second exposure to
tumor cells.
We observed enhanced
tumor rejection in DGKζ - deficient
mice and DKO
mice relative to WT or Cbl - b — deficient
mice.